Emergent Biosolutions, Inc. (EBS) News
Filter EBS News Items
EBS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EBS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest EBS News From Around the Web
Below are the latest news stories about EMERGENT BIOSOLUTIONS INC that investors may wish to consider to help them evaluate EBS as an investment opportunity.
Those who invested in Emergent BioSolutions (NYSE:EBS) a year ago are up 365%While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock... |
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that Joe C. Papa, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 PM PST. The audio link for Emergent's session may be accessed here and will be live for up to 30 days. The company’s |
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense (DoD). The first delivery, which was valued at approximately $7 million began in December 2024, and remaining deliveries are expected in 2025. “We’re pleased to continue our work with the U.S. Department of Defense to supply B |
Why Emergent BioSolutions Stock Blasted Higher TodayAn analyst initiated coverage of Emergent BioSolutions (NYSE: EBS) stock as the last trading week of 2024 kicked off, and investors reacted quite positively to the move. Emergent, which benefits from a wider-than-average range of revenue-generating activities, is now being tracked by H.C. Wainwright's Raghuram Selvaraju. According to reports, Selvaraju believes Emergent is well diversified in its offerings, and it is active in several medical segments that have fine potential for growth. |
Emergent Stock Skyrockets 251% YTD: How to Play the Stock?The appointment of CEO John Papa earlier this year has been a key driver of EBS' strong performance, sparking significant investor optimism. |
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)GAITHERSBURG, Md., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services has awarded a $50 million option to Emergent’s existing contract (HHSO100201600030C) for the acquisition of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted). Deliveries are expected to begin this |
Why Emergent BioSciences Stock Plummeted TodayEmergent BioSolutions (NYSE: EBS) saw its shares tumble on Tuesday, due to news of a share sell-off. The selling parties are mainly entities affiliated with OHA Agency, a business that provided a $250 million term loan to Emergent in August. Emergent stressed in its filing that it will receive no monies from these sales, as it is not one of the selling parties. |
Emergent BioSolutions Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagEmergent BioSolutions ( NYSE:EBS ) Third Quarter 2024 Results Key Financial Results Revenue: US$293.8m (up 8.6% from 3Q... |
Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...Emergent BioSolutions Inc (EBS) reports a robust financial performance with a 9% revenue increase and significant debt reduction, despite challenges in Narcan sales. |
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024On Thursday, Emergent BioSolutions Inc. (NYSE:EBS) stock is trading higher on mixed third-quarter earnings and a new mpox trial in Africa. The company reported third-quarter sales of $293.8 million, up 9% year over year, with the management guidance of $265 million–$315 million, and missing the consensus of $297.5 million. The company reported an adjusted EPS of $1.37, a turnaround from a loss of $1.09 a year ago, beating the consensus of $0.14. Revenues from Narcan (naloxone HCl) Nasal Spray de |